STOCK TITAN
  1. Home
  2. News
  3. TSVT

2seventy bio Inc - TSVT STOCK NEWS

Welcome to our dedicated news page for 2seventy bio (Ticker: TSVT), a resource for investors and traders seeking the latest updates and insights on 2seventy bio.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect 2seventy bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of 2seventy bio's position in the market.

News
2seventy bio to Host Investor Call at 8:00am ET on Tuesday, December 12 to Discuss Data from KarMMa-3 and KarMMa-2 Studies of Abecma (idecabtagene vicleucel)
Rhea-AI Summary
2seventy bio, Inc. (TSVT) to Host Conference Call Highlighting Data Presented at ASH Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
conferences
-
News
2seventy bio Reiterates Commitment to Maximizing Shareholder Value
Rhea-AI Summary
2seventy bio, Inc. (NASDAQ: TSVT) reaffirms its dedication to maximizing shareholder value by considering all options to achieve this goal. The company is focused on making its therapies available to patients, driving value for shareholders, and supporting its employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.3%
Tags
none
-
News
Engine Capital Sends Letter to 2seventy’s Board of Directors Outlining Steps to Maximize Shareholder Value
Rhea-AI Summary
Engine Capital LP, which owns approximately 3% of 2seventy bio, Inc.’s (Nasdaq: TSVT) outstanding shares, believes that the company could be conservatively worth ~$9 per share if it exclusively focuses on its most-valuable asset Abecma, reduces corporate overhead and makes improvements to the composition of the management team and board. The company is currently trading at a market capitalization of just $100 million, despite having a cash balance of $284 million and a 50% profit interest in Abecma that is likely worth at least a few hundred million dollars.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.55%
Tags
management
News
Bristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
Rhea-AI Summary
Bristol Myers Squibb (BMY) and 2seventy bio, Inc. (TSVT) announced that the FDA's Oncologic Drugs Advisory Committee (ODAC) will review data for the sBLA for Abecma for earlier lines of triple-class exposed relapsed or refractory multiple myeloma (RRMM) based on Phase 3 KarMMa-3 study. The ODAC meeting date is pending, and the PDUFA target action date has been extended. The companies await the FDA's decision and anticipate the ODAC to review data related to the secondary endpoint of overall survival (OS). The KarMMa-3 study showed significant improvement in progression-free survival (PFS) and a consistent safety profile of Abecma. Final PFS and interim OS data will be presented at the 2023 ASH Annual Meeting. Regulatory applications for Abecma in earlier lines of therapy are under review in Japan, Europe, and Switzerland.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.82%
Tags
none
-
News
2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) - Abecma (idecabtagene vicleucel) data to be presented at ASH 2023; multiple new analyses of KarMMa-3 and KarMMa-2c add to growing body of data supporting the potential safety and efficacy of Abecma in earlier lines of treatment. Abecma generated $69 million U.S. commercial revenue in the third quarter of 2023; $302 million U.S. commercial revenue year-to-date. Two solid tumor programs positioned to enter clinical trials in 2024. Ended quarter with $284.3 million cash, cash equivalents, and marketable securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
earnings
-
News
2seventy bio to Report Third Quarter 2023 Financial Results on November 14, 2023
Rhea-AI Summary
2seventy bio, Inc. (Nasdaq: TSVT) to announce Q3 2023 financial results and host conference call for business update. Participants can access the live webcast on the company's website. Replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.54%
Tags
conferences earnings
News
Deep Genomics Announces the Appointment of Brian O’Callaghan as CEO
Rhea-AI Summary
Brian O’Callaghan appointed CEO of Deep Genomics as part of strategic plan to evolve into a forward-integrated biopharmaceutical company. Founder Brendan Frey becomes chief innovation officer. Chip Baird appointed chair of the board.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.88%
Tags
management
-
News
2seventy bio Announces Strategic Restructuring to Prioritize Growth of Abecma, Streamline Pipeline Advancement and Preserve Financial Runway
Rhea-AI Summary
2seventy bio, Inc. announces workforce reduction and restructuring to achieve $130+ million savings by 2024-2025
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
-
News
2seventy bio and JW Therapeutics Announce Intent To Expand Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies and Autoimmune Therapies
Rhea-AI Summary
2seventy bio and JW Therapeutics plan to expand their strategic alliance, adding up to two additional candidates from the 2seventy portfolio in solid tumor indications and autoimmune disease. The initial MAGE-A4 T-cell program is running ahead of schedule and on track to initiate an investigator-initiated study in China by the end of this year. The expansion demonstrates the success of the collaboration and aims to accelerate the development of potential new medicines with breakthrough therapeutic value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
partnership
News
2seventy bio to Participate in the 2023 Morgan Stanley Global Healthcare Conference
Rhea-AI Summary
2seventy bio, Inc. to participate in fireside chat at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
Stock TSVT logo
2seventy bio Inc

Nasdaq:TSVT

TSVT Rankings

#3673 Ranked by Market Cap
#5421 Ranked by Stock Gains
N/A Ranked by Dividends

TSVT Stock Data

258.61M
49.61M
2.5%
98.41%
13.26%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cambridge

About TSVT

we are an immuno-oncology cell therapy company focused on discovering and developing new therapies that truly disrupt the cancer treatment landscape. our name, 2seventy bio, is inspired by the maximum speed of translating human thought into action—270 miles per hour, and at 2seventy, we think in the language of time. with a deep understanding of cancer cell metabolism, genomics, and the human body’s immune response to tumor cells, we’re applying this knowledge and expertise to new classes of cellular therapies that are designed to “think” smarter and faster than cancer. it is this mindset that propels us forward because we know that time matters -- every day, every minute, every second -- to people living with cancer